Research Topics
| Manuel CrespoSummaryAffiliation: Hospital Universitari Vall d'Hebron Country: Spain Publications
| Collaborators
|
Detail Information
Publications
Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAARTManuel Crespo
Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
Enferm Infecc Microbiol Clin 26:27-31. 2008..The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations...
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimenManuel Crespo
Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
J Antimicrob Chemother 62:793-6. 2008..However, data available on the efficacy of this therapy in co-infected patients who failed a former interferon-based regimen are limited...- Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patientsManuel Crespo
Infectious Diseases Department, Spain
AIDS 21:477-81. 2007..To investigate the utility of a week-4 virological response for sustained response prediction in hepatitis C virus (HCV) genotype 3/HIV-co-infected patients treated with interferon and ribavirin for 24 weeks... - Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patientsManuel Crespo
Infectious Diseases Department, Hospital Universitari Vail d Hebron, Universitat Autonoma de Barcelona, Spain
Antivir Ther 12:1217-23. 2007..Therefore, it has been suggested that monitoring RBV serum levels could be used to drive dose modification and to optimize management of HCV-infected patients receiving combination treatment... - Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trialEva Van den Eynde
Infectious Diseases Department, Vall d Hebron Hospital, Autonomous University of Barcelona, Spain
Clin Infect Dis 48:1152-9. 2009..To study the feasibility of a response-guided therapy for chronic hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus (HIV) in a tertiary care hospital... - Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimenEsteban Ribera
Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
AIDS 20:1131-9. 2006..To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV) and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults... - Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trialAdrian Curran
Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
Antivir Ther 17:711-8. 2012.... - Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimenJoaquin Burgos
Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
J Antimicrob Chemother 67:1453-8. 2012..To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen... - Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patientsJoaquin Burgos
Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
J Antimicrob Chemother 67:2479-86. 2012..To assess the effectiveness of simplification to a dual antiretroviral regimen containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced HIV-1-infected patients... - Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosisEsteban Ribera
Infectious Diseases Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
J Antimicrob Chemother 59:690-7. 2007..To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs)... - Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study)Esteban Ribera
Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Barcelona, Spain
HIV Clin Trials 9:407-17. 2008..Lipoatrophy is the most stigmatizing side effect of stavudine therapy. We assessed the long-term effects of replacing stavudine with tenofovir in HIV-infected patients with lipoatrophy... - Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patientsEva Van den Eynde
Infectious Diseases Service, Hospital Vall d Hebron, Medicine Department, Universitat Autonoma de Barcelona, Spain
AIDS 24:975-82. 2010..Our main objective was to study the ability of week 12 viral response [early virologic response (EVR)] to predict long-term outcome in patients treated for 48 weeks... - Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudyAdrian Curran
Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Infectious Diseases Department, Spain
AIDS 26:475-81. 2012..To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r... - Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon systemEva Van den Eynde
Infectious Diseases Department, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
Antivir Ther 16:887-93. 2011..Here, we studied the effect of abacavir, tenofovir or lamivudine addition on the suppressive activity of ribavirin in an HCV RNA replicon system... 
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adultsEsteban Ribera
Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
Antimicrob Agents Chemother 48:4256-62. 2004....- Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patientsAdrian Curran
Infectious Diseases Department, Hospital Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain
J Antimicrob Chemother 65:2195-203. 2010..To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance... - Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohortManuel Crespo
Hospital Universitari Vall d Hebron, Barcelona, Spain
J Antimicrob Chemother 63:189-96. 2009..In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients... - Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in childrenJoaquin Burgos
Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
J Acquir Immune Defic Syndr 59:31-8. 2012..We conducted a multicenter study to analyze differences in clinical presentation of IPD between HIV-infected and non-HIV-infected adults in the prevaccine and postvaccine era... - Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosidesJoan Gavalda
Infectious Diseases Research Laboratory, Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Avda Vall d Hebron, 119 129, 08035 Barcelona, Spain
J Antimicrob Chemother 52:514-7. 2003..It also determines whether adding ceftriaxone to ampicillin and gentamicin increases the effectiveness against experimental enterococcal endocarditis resulting from E. faecalis... - Lactic acidosis related to nucleoside therapy in HIV-infected patientsVicenc Falco
Infectious Diseases Division, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, P masculine Vall d Hebron 119 129 08035, Barcelona, Spain
Expert Opin Pharmacother 4:1321-9. 2003..Therapy is based on supportive measures and discontinuation of all antiretroviral drugs. Administration of essential vitamin coenzymes, electron acceptors and L-carnitine may be useful in some cases... - Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineCesar Fisac
Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
AIDS 19:917-25. 2005..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir... - Tuberculous trochanteric bursitis: report of 5 cases and literature reviewManuel Crespo
Hospital Universitari Vall d'Hebron, Universitat Autonoma, Barcelona, Spain
Scand J Infect Dis 36:552-8. 2004..This report presents 5 new cases of TTB and a review of the literature (1981-2003), with emphasis on clinical and radiological findings and treatment, in order to investigate the optimum therapeutic approach...